A lung cancer survivor with abnormal stricture of the trachea and bronchus receives a customized, 3D-printed silicone stent, an approach pioneered at Cleveland Clinic.
Can metastases to the lung occur from cancers that were treated several years ago?
A study recently published in Lancet Oncology found ALT-803 + nivolumab safe and with early signs of efficacy in patients with mNSCLC considered PD-1-treatment resistant.
Preliminary data from the first prospective clinical trial shows higher blood-based tumor burden works as biomarker for effective atezoli-zumab treatment in non-small cell lung cancer patients.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A study presented at the USCAP 2018 Annual Meeting finds that insulinoma-associated protein 1 (INSM1) is a reliable marker for the diagnosis of neuroendocrine lung tumors, including small-cell lung carcinoma.
A computer-assisted analysis of digital tissue microarray slides could soon help identify which NSCLC patients are likely to face early recurrence.
In addition to determining the probability of finding N2 or N3 disease on EBUS-TBNA the model is also able to predict the presence of mediastinal disease when EBUS-TBNA nodal sampling is negative.
The potential for molecular biomarkers to tip the balance from benefit to harm in lung cancer screening and nodule diagnosis and to enhance risk prediction warrants a robust discussion about how we determine their accuracy and readiness for clinical use.
Based on our experience at Cleveland Clinic, we favor centralized management of screening decisions in our health system, detailed and thorough shared decision-making visits with one-year follow up and concrete plans for managing incidental findings.
Primary care physicians play a vital role in detecting cancers at earlier stages. Lung cancer has the highest mortality rate of any cancer in the U.S., and screening can be controversial.